产品
编 号：F003301
分子式：C21H15F2N2O
分子量：349.35
分子式：C21H15F2N2O
分子量：349.35
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
5780
In-stock
2mg
3500
In-stock
5mg
5250
In-stock
10mg
7500
In-stock
结构图
CAS No: 1006378-90-0
产品详情
生物活性：
p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.
体内研究：
p38 MAPK-IN-1 (Compound 4; 1 mg/kg for iv and 10 mg/kg for po) has a t1/2 of 7.4 hours and CL of 2.7 mL/min/kg for iv, and a Cmax of 5.3 μM for po in male wistar rats. p38 MAPK-IN-1 dose-dependently inhibits TNFα production with an ED50 of 0.5 mg/kg. Animal Model:Male wistar rats
Dosage:10 mg/kg for po and 1 mg/kg for iv (Pharmacokinetic Analysis)
Administration:Po and iv
Result:Had a t1/2 of 7.4 hours and CL of 2.7 mL/min/kg for iv, and a Cmax of 5.3 μM for po.
p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.
体内研究：
p38 MAPK-IN-1 (Compound 4; 1 mg/kg for iv and 10 mg/kg for po) has a t1/2 of 7.4 hours and CL of 2.7 mL/min/kg for iv, and a Cmax of 5.3 μM for po in male wistar rats. p38 MAPK-IN-1 dose-dependently inhibits TNFα production with an ED50 of 0.5 mg/kg. Animal Model:Male wistar rats
Dosage:10 mg/kg for po and 1 mg/kg for iv (Pharmacokinetic Analysis)
Administration:Po and iv
Result:Had a t1/2 of 7.4 hours and CL of 2.7 mL/min/kg for iv, and a Cmax of 5.3 μM for po.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备